Corporate News - Archive

  • Group revenue: +9.5% to EUR 92.7 million (Q1 2024: EUR 84.7 million)
  • EBITDA: +22% to EUR 10.0 million (Q1 2024: EUR 8.2 million)
  • EBIT: +29% to EUR 8.8 million (Q1 2024: EUR 6.8 million)
  • EBIT margin: 9.5% (Q1 2024: 8.1%)
  • EBT: +23% to EUR 8.6 million (Q1 2024: EUR 7.0 million)
  • Earnings per share: EUR 0.31 (Q1 2024: EUR 0.26)

| Investor News

  • Group revenue increased by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA rose by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT grew by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT increased by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Beauty segment revenue rose by 30% to EUR 91.7 million (previous year: EUR 70.8 million)
  • Equity ratio improved from 67% to 71%

| Investor News

  • Group revenue: increase by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA: increase by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT: increase by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT: increase by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Earnings per share: increase of 57% to EUR 0.85 (previous year: EUR 0.54)
  • Equity ratio: increase from 67% to 71%

| Ad-hoc news

HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.

A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.

The company will provide further information in due course.

| Investor News

  • Group: sales +8.7% to EUR 257.22 million and EBIT +70.7% to EUR 22.09 million
  • Beauty segment growth driver with sales +33.5% to EUR 71.02 million
  • EBIT in the Beauty segment +30.4% to EUR 16.26 million
  • Medium-term target confirmed: World's leading private provider of beauty treatments

| Investor News

  • Group: sales +11.2% to EUR 167.7 million and EBIT +98.8% to EUR 14.5 million
  • Earnings per share increased from EUR 0.17 to EUR 0.53
  • Beauty segment: sales +30.6% and EBIT +24.3%
  • Profitable growth to be continued

As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.

Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone.

In the first quarter of 2024, the M1 Group increased its consolidated sales by 9.6% from EUR 76.8 million to EUR 84.7 million. In comparison, operating earnings before interest and taxes (EBIT) increased at a disproportionately high rate. M1 improved Group EBIT by 70% from EUR 4.0 million to EUR 6.8 million. The Group EBIT margin increased accordingly from 5.3% to 8.1%.

| Investor News

  • Group sales increase by 10.9% to € 316.3 million in 2023
  • Highly profitable beauty segment drives growth with an increase of 17.6% to EUR 70.8 million
  • Consolidated net profit (after minority interests) improved from EUR 4.3 million to EUR 10.3 million
  • Dividend proposal of EUR 0.50 per share
  • Medium-term forecast for the Beauty segment: target sales of EUR 200 to 300 million by 2029 with an EBIT margin of at least 20%